| 000 | 01813 a2200517 4500 | ||
|---|---|---|---|
| 005 | 20250515161059.0 | ||
| 264 | 0 | _c20090820 | |
| 008 | 200908s 0 0 eng d | ||
| 022 | _a1464-3405 | ||
| 024 | 7 |
_a10.1016/j.bmcl.2009.01.097 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aJahangir, Alam | |
| 245 | 0 | 0 |
_aIdentification and SAR of novel diaminopyrimidines. Part 2: The discovery of RO-51, a potent and selective, dual P2X(3)/P2X(2/3) antagonist for the treatment of pain. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cMar 2009 |
||
| 300 |
_a1632-5 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 |
_aAdenosine Triphosphate _xchemistry |
| 650 | 0 | 4 |
_aAnalgesics _xchemical synthesis |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCHO Cells |
| 650 | 0 | 4 |
_aChemistry, Pharmaceutical _xmethods |
| 650 | 0 | 4 | _aCricetinae |
| 650 | 0 | 4 | _aCricetulus |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aDrug Evaluation, Preclinical |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInhibitory Concentration 50 |
| 650 | 0 | 4 | _aModels, Chemical |
| 650 | 0 | 4 |
_aPain _xdrug therapy |
| 650 | 0 | 4 | _aPurinergic P2 Receptor Antagonists |
| 650 | 0 | 4 |
_aPyrimidines _xchemical synthesis |
| 650 | 0 | 4 |
_aReceptors, Purinergic P2 _xchemistry |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aAlam, Muzaffar | |
| 700 | 1 | _aCarter, David S | |
| 700 | 1 | _aDillon, Michael P | |
| 700 | 1 | _aBois, Daisy Joe Du | |
| 700 | 1 | _aFord, Anthony P D W | |
| 700 | 1 | _aGever, Joel R | |
| 700 | 1 | _aLin, Clara | |
| 700 | 1 | _aWagner, Paul J | |
| 700 | 1 | _aZhai, Yansheng | |
| 700 | 1 | _aZira, Jeff | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 19 _gno. 6 _gp. 1632-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2009.01.097 _zAvailable from publisher's website |
| 999 |
_c18673642 _d18673642 |
||